Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Retained Earnings (2020 - 2025)

Cytek Biosciences' Retained Earnings history spans 6 years, with the latest figure at -$101.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 635962.5% year-over-year to -$101.7 million; the TTM value through Dec 2025 reached -$101.7 million, down 635962.5%, while the annual FY2025 figure was -$101.7 million, 635962.5% down from the prior year.
  • Retained Earnings reached -$101.7 million in Q4 2025 per CTKB's latest filing, down from -$57.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $897000.0 in Q4 2021 to a low of -$101.7 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$19.2 million, with a median of -$18.4 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 1280.0% in 2021, then plummeted 635962.5% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $897000.0 in 2021, then plummeted by 177.7% to -$697000.0 in 2022, then plummeted by 4086.23% to -$29.2 million in 2023, then skyrocketed by 100.05% to $16000.0 in 2024, then tumbled by 635962.5% to -$101.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Retained Earnings are -$101.7 million (Q4 2025), -$57.7 million (Q3 2025), and -$38000.0 (Q2 2025).